258 related articles for article (PubMed ID: 15951728)
1. The clinical significance of viral fitness.
Geretti AM
J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
[TBL] [Abstract][Full Text] [Related]
2. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral resistance.
Geretti AM
J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
[No Abstract] [Full Text] [Related]
4. Current insights into reverse transcriptase inhibitor-associated resistance.
Wainberg MA; White AJ
Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
[No Abstract] [Full Text] [Related]
5. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
6. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
8. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
9. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C
J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
[TBL] [Abstract][Full Text] [Related]
11. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay.
Liuzzi G; Chirianni A; Zaccarelli M; Zinzi D; Esposito V; Guadagnino V; Antinori A; Piazza M
In Vivo; 2004; 18(4):509-12. PubMed ID: 15369193
[TBL] [Abstract][Full Text] [Related]
12. Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
Garcia F; Alvarez M; Fox Z; Garcia-Diaz A; Guillot V; Johnson M; Chueca N; Phillips A; Hernández-Quero J; Geretti AM
Antivir Ther; 2011; 16(3):373-82. PubMed ID: 21555820
[TBL] [Abstract][Full Text] [Related]
13. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa.
Barth RE; Wensing AM; Tempelman HA; Moraba R; Schuurman R; Hoepelman AI
AIDS; 2008 Oct; 22(16):2210-2. PubMed ID: 18832885
[TBL] [Abstract][Full Text] [Related]
14. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the concept of a genetic barrier to resistance.
Rusconi S
J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
[No Abstract] [Full Text] [Related]
16. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of resistance testing.
Stebbing J; Gazzard BG
J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
[No Abstract] [Full Text] [Related]
18. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
Soriano V
Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
[TBL] [Abstract][Full Text] [Related]
19. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy for patients failing their current antiretroviral regimen.
Albrecht MA
AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
